News | March 01, 2011

Court Rules for Hologic in Brachytherapy Patent Infringement Suit

March 1, 2011 – The U.S. Court of Appeals for the Federal Circuit has ruled in favor of Hologic and against SenoRX regarding patent infringement involving breast brachytherapy systems.

The court reversed previous decisions reached by the U.S. District Court for the Northern District of California, which were in favor of SenoRx.

The patent infringement lawsuit was filed in 2008 by Hologic, Cytyc Corp. and Hologic L.P. against SenoRx (acquired by C.R. Bard in July 2010). It alleges infringement of claims 1 and 8 of Hologic's U.S. patent 6,482,142 by the SenoRx Contura breast brachytherapy product. The district court had granted SenoRx summary judgment of invalidity as to claim 1 and, following a jury verdict on Dec. 17, 2009, entered a judgment of invalidity as to claim 8.

On Feb. 4, 2011, citing an incorrect claim construction, the Appeals Court reversed the district court's granting of summary judgment of invalidity as to claim 1 and also reversed the district court's judgment of invalidity as to claim 8. In the same 2008 infringement suit, the district court found sales of the SenoRx Contura to infringe claim 8. That judgment of infringement was not appealed by SenoRx.

The matter has been remanded to the district court for further proceedings consistent with the Appeals Court's judgment.

For more information: www.hologic.com

Related Content

​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Cleveland Clinic Leads Development of New Guidelines for Radiation in Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | October 31, 2017
October 31, 2017 — Cleveland Clinic researcher Chirag Shah, M.D., recently led the development of updated guidelines
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Pelvic Radiation Confirmed as Standard of Care for High-Risk, Early-Stage Endometrial Cancer
News | Brachytherapy Systems, Women's Healthcare | September 28, 2017
In a new phase III trial report, recurrence-free and overall survival rates for women with stage I-II high-risk...
China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer
News | Brachytherapy Systems, Women's Healthcare | August 30, 2017
iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Australia's Monash Cancer Centre Treats First Early-Stage Breast Cancer Patient With Xoft System
News | Brachytherapy Systems, Women's Healthcare | May 01, 2017
iCAD Inc. announced the first early-stage breast cancer patient was treated in Australia with intraoperative radiation...
New Clinical Data on Xoft System Presented at American Brachytherapy Society Annual Meeting
News | Brachytherapy Systems, Women's Healthcare | April 20, 2017
iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft...
Concure Oncology, Breast Microseed Treatment, one day, low-dose rate brachytherapy, LDR
Technology | Brachytherapy Systems, Women's Healthcare | May 12, 2016
Concure Oncology/Breast Microseed Inc. announced the launch of its one-time, one-hour radiation treatment option for...
Overlay Init